



<b>CMP</b>	1592
<b>Start Date</b>	06 <sup>th</sup> Nov 2020
<b>End Date</b>	11 <sup>th</sup> Nov 2020
<b>Ex Date</b>	12 <sup>th</sup> Nov 2020
<b>Record Date</b>	13 <sup>th</sup> Nov 2020
<b>Price</b>	1850/share
<b>Face Value</b>	2/share
<b>Offer Size</b>	7,35,000 Eq Shares
<b>Offer Size</b>	Rs 13597,50,000
<b>Manager</b>	Indusind Bank

Ajanta Pharma is a specialty pharmaceutical formulation company engaged in the development, manufacture and marketing of quality finished dosages. The Company has a well-diversified and de-risked business model with over 70% of business coming from a wide range of branded generic products in over 30 countries in Asia (including India) and Africa. The balance 30% is contributed by generics business in USA and anti-malaria institutional business in Africa.

#### Details of Buyback:

The Company is proposing to buyback up to 7,35,000 (Seven Lakh Thirty Five Thousand) fully paid-up equity shares of face value of Rs 2 each representing 0.84% of the total number of Equity Shares in the total paid-up share capital of the Company (calculated on the basis of the total paid-up share capital of the Company as on October 31, 2020). The Buyback offer price of rs 1,850/- (Rupees One Thousand Eight Hundred and Fifty only) per Equity Share .

### Recommendation

Company has posted strong set of numbers in Q2FY21. Company's strategy to invest in different markets and geographies in a sustained manner has made company's business model quite resilient. Company have also built competitive edge in each of the markets by identifying unmet needs and offering customized products. This edge provides company continuous growth . The Company continues to strengthen product portfolio through new launches, many of them being first-to-market products, offering significant patient benefits. Apart from new launches, many of the Company's existing products continue to grow their market share. Ajanta Pharma's India business continued to perform well steered by strong focus on high growth specialty segments. As per IMS MAT March 2020, the Company outgrew Indian Pharmaceutical Market (IPM) recording 13% growth compared to 11% for the industry, maintaining its healthy track record for last 5 years. Company has also improved its ranking in IPM to 30<sup>th</sup> against 31<sup>st</sup> last year.

Hence looking after all above company looks strong from long term perspective. However investors with short term horizon can participate in buyback process while for long term investors we recommend to hold stock.

### FINANCIAL REVIEW (Consolidated)

(Rs. in Crore)

Particulars	Sept-21	Sept-20	YoY%	Jun-21	QoQ%	FY20	FY19	Growth %
<b>Tot Income</b>	715.91	642.76	11.38	668.20	7.14	2587.87	2055.37	25.91
<b>PBIDT</b>	274.25	177.64	54.39	223.22	22.86	683.33	566.43	20.64
<b>PAT</b>	170.22	116.36	46.29	147.76	15.20	467.70	386.97	20.86
<b>PBIDTM %</b>	38.31	27.64	38.61	33.41	14.67	26.41	27.56	-4.17
<b>PATM%</b>	23.78	18.10	31.34	22.11	7.55	18.07	18.83	-4.04
<b>EPS</b>	19.41	13.27	46.29	16.85	15.19	53.33	44.12	20.87

[For Disclosure & Disclaimer, click here.](#)